Background/objectives <p>This study aimed to compare one-year clinical outcomes of two faricimab treatment strategies in patients with previously treated exudative neovascular age-related macular degeneration (nAMD): (1) immediate switch to treat-and-extend dosing (T&amp;E), and (2) initiation with a four-dose induction (“loading”) regimen.</p> Subject/methods <p>Retrospective comparing two cohorts of pretreated nAMD patients with 12 months of follow-up who were either switched to Faricimab with immediate T&amp;E dosing (Lucerne protocol, “on-the-fly”), or initiated with a four-dose induction phase (Lugano protocol,“re-loading”). Both cohorts were subsequently managed according to a T&amp;E regimen. Demographic and clinical data, including prior intravitreal agents, best-corrected visual acuity (BCVA), central subfield thickness (CST) on optical coherence tomography (OCT), and length of treatment intervals were analysed. Multivariable models were adjusted for baseline differences.</p> Results <p>Both cohorts (Lucerne, 183 eyes; Lugano, 33 eyes) were similar in baseline characteristics. BCVA improved by 0.81 ETDRS letters in Lucerne and by 2.42 in the Lugano cohort (<i>p</i> = 0.250). CRT decreased by -38.3&#xa0;μm in Lucerne and by -57.8&#xa0;μm in Lugano (<i>p</i> = 0.053). Treatment intervals increased by 2.2 weeks in Lucerne and 3.4 weeks in Lugano (<i>p</i> = 0.092). At 12 months, 15.3% of Lucerne patients and 27.3% of Lugano patients achieved intervals ≥ 12 weeks, with significantly higher odds of extension in Lugano (OR 3.87; <i>p</i> = 0.013).</p> Conclusions <p>Both cohorts showed anatomical and functional improvements after switching to faricimab. The Lugano cohort, using a four-dose induction phase, showed longer treatment intervals, suggesting better disease stability.</p> Clinical trial number <p>Not applicable.</p>